Clinical applications of genome studies.

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med (2002) 24.07

Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14

Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet (2011) 6.06

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med (2003) 6.06

Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77

The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (2016) 3.21

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med (2015) 2.42

Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol (2014) 2.06

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood (2013) 1.84

Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol (2013) 1.73

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. Blood (2016) 1.66

Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leuk Lymphoma (2015) 1.42

From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol (2012) 1.24

Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09

B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol (2015) 1.08

Precision therapy for lymphoma--current state and future directions. Nat Rev Clin Oncol (2014) 1.00

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J Mol Diagn (2017) 0.98

The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol (2015) 0.88

Drug pipeline Q4 2015. Nat Biotechnol (2016) 0.80

The landscape of new drugs in lymphoma. Nat Rev Clin Oncol (2016) 0.78

Diffuse large B-cell lymphoma: changing treatment paradigms. Oncology (Williston Park) (2014) 0.77

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol (2015) 2.84

CUDC-907 in relapsed/refractory diffuse Large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase 1 trial. Haematologica (2017) 0.75

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting. Clin Trials (2016) 0.75